Trial Profile
A retrospective study to evaluate the change of prostate specific antigen and bone metastases of castration resistant prostate cancer treated with Enzalutamide,Abiraterone and/or Docetaxel
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2017
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 21 Mar 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium